Trends of incidence and age in adults with testicular germ cell tumors: a two-decade multicenter retrospective study

Background Testicular germ cell tumors (GCTs) are the most common type of cancer in adolescent boys and young adult men, but the age at onset has been increasing. However, little is known regarding the incidence and age of patients with testicular GCTs in Japan because the incidence there is low. Methods We retrospectively reviewed the medical records of patients with GCTs in seven hospitals between 2001 and 2021. We compared the incidences of testicular GCTs, ages at onset, pathological types (seminoma or nonseminoma), and clinical stages in patients with GCTs between the periods 2001–2010 and 2011–2021. Results We identified 193 adults (≥20 years of age) with testicular GCTs; their median age was 37 years [interquartile range (IQR), 29–47 years]. Of these patients, 87 (45.1%) were ≥40 years of age at diagnosis. The proportion of patients aged ≥40 years was significantly higher in the period 2011–2021 (54.8%) than in 2001–2010 (30.8%; P=0.001). The incidence of seminoma was significantly higher in the period 2011–2021, but clinical stage did not differ significantly between the two periods. The population-adjusted incidence among patients in their 40s was 3.4-fold higher in 2011–2021 than in 2001–2010. Conclusions The number of patients with GCTs aged ≥40 years was significantly higher in 2011–2021, even in a population-adjusted analysis. Treatment strategies need to be adapted to older testicular germ cell tumor patients.

[1]  N. Tsuchiya,et al.  Body composition changes following chemotherapy for testicular germ cell tumor: obesity is the long-term problem , 2021, Asian journal of andrology.

[2]  Terukazu Nakamura,et al.  Fertility and reproductive technology use in testicular cancer survivors in Japan: A multi‐institutional, cross‐sectional study , 2021, International journal of urology : official journal of the Japanese Urological Association.

[3]  H. Nishiyama,et al.  Advanced germ cell tumor patients undergoing post‐chemotherapy retroperitoneal lymph node dissection: Impact of residual teratoma on prognosis , 2021, International journal of urology : official journal of the Japanese Urological Association.

[4]  Yasuhisa Fujii,et al.  First‐line combination chemotherapy with etoposide, ifosfamide and cisplatin for the treatment of disseminated germ cell cancer: Efficacy and feasibility in current clinical practice , 2021, International journal of urology : official journal of the Japanese Urological Association.

[5]  Terukazu Nakamura,et al.  Validation study of the Japanese version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire‐Testicular Cancer 26 for patients with testicular cancer , 2020, International journal of urology : official journal of the Japanese Urological Association.

[6]  Y. Arai,et al.  Trends in Age and Histology of Testicular Cancer from 1980-2019: A Single-Center Study. , 2020, The Tohoku journal of experimental medicine.

[7]  T. Uchiumi,et al.  Genomic characteristics revealed by targeted exon sequencing of testicular germ cell tumors in Japanese men , 2020, International journal of urology : official journal of the Japanese Urological Association.

[8]  H. Nishiyama,et al.  Recent malignant testicular tumor trend in Japan, a country with an aging population: a large-scale study of 2012-2015 hospital-based cancer registry data. , 2020, Japanese journal of clinical oncology.

[9]  E. Amini,et al.  Global, regional and national burden of testicular cancer, 1990–2016: results from the Global Burden of Disease Study 2016 , 2019, BJU international.

[10]  Masami Watanabe,et al.  Comparison of the predictive value among inflammation‐based scoring systems for bleomycin pulmonary toxicity in patients with germ cell tumors , 2019, International journal of urology : official journal of the Japanese Urological Association.

[11]  C. Bouchardy,et al.  Testicular cancer in Geneva, Switzerland, 1970–2012: incidence trends, survival and risk of second cancer , 2019, BMC Urology.

[12]  P. Boström,et al.  Time trends and occupational variation in the incidence of testicular cancer in the Nordic countries , 2018, BJU international.

[13]  C. Shimizu,et al.  Current situation of cancer among adolescents and young adults in Japan , 2018, International Journal of Clinical Oncology.

[14]  Terukazu Nakamura,et al.  Chemotherapy for metastatic testicular cancer: The first nationwide multi‐institutional study by the Cancer Registration Committee of the Japanese Urological Association , 2018, International journal of urology : official journal of the Japanese Urological Association.

[15]  W. Mackillop,et al.  Temporal trends in management and outcomes of testicular cancer: A population‐based study , 2018, Cancer.

[16]  Masami Watanabe,et al.  Prognostic impact of bleomycin pulmonary toxicity on the outcomes of patients with germ cell tumors , 2018, Medical Oncology.

[17]  Niels Jørgensen,et al.  Temporal trends in sperm count: a systematic review and meta-regression analysis , 2017, Human reproduction update.

[18]  K. Katanoda,et al.  Childhood, adolescent and young adult cancer incidence in Japan in 2009–2011 , 2017, Japanese journal of clinical oncology.

[19]  T. Kawai,et al.  Clinical characteristics of testicular germ cell tumors in patients aged 50 years and older: A large‐scale study from the Cancer Registration Committee of the Japanese Urological Association , 2017, International journal of urology : official journal of the Japanese Urological Association.

[20]  D. Krewski,et al.  Dietary risk factors for testicular carcinoma , 2003, International journal of cancer.

[21]  S. Leeder,et al.  A population based study , 1993, The Medical journal of Australia.

[22]  D. Dearnaley,et al.  Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.